SENS News and Press, Senseonics Holdings Inc. From 05/23/22

Senseonics received FDA approval earlier this year for its 180-day continuous glucose monitoring system. Management expects sales to pick up in the second half of this year, along with the rollout of products in the U.S. and Europe. Despite product developments and plenty of opera...

Gainers: Cullinan Oncology (CGEM) +21%. Concert Pharmaceuticals (CNCE) +20%. Babylon Holdings BBLN +16%. Blue Water Vaccines (BWV) +14%.  ViewRay (VRAY) +10%. Losers: Eargo (EAR) -24%. Senseonics (SENS) -14%. Ascendis Pharma (ASND) -11%. Evaxion Biotech...

Senseonics Holdings, Inc. (SENS) Q1 2022 Earnings Conference Call May 10, 2022 16:30 ET Company Participants Malcolm MacLeod - Investor Relations Timothy Goodnow - President & Chief Executive Officer Nick Tressler - Chief Financial Officer, Secretary & Treasurer Conference Call Partic...

Shares of Senseonics (NYSE:SENS) are down 9% in post-market trading despite releasing Q1 2022 results that beat on the top and bottom lines. The continuous glucose monitoring system maker swung to net income of $86.7M ($0.19 basic EPS) in the quarter from a net loss of $249.5M in th...

Senseonics press release (NYSE:SENS): Q1 GAAP EPS of -$0.03 beats by $0.01. Revenue of $2.48M (-13.0% Y/Y) beats by $0.24M. Shares -3%. Outlook: Senseonics reiterates the expectation for full year 2022 global net revenue to be in the range of $14.0 million to $18.0 million vs. consensus of $1...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31, 202...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The number of zombie companies ebbs and flows with economic cycles and usually increases during recessionary periods. Diebold Nixdorf  ( DBD ): The ATM machines business contributes to top-line growth as cust...

Tandem Diabetes Care (NASDAQ:TNDM) is trading sharply lower in the morning hours Thursday after the insulin pump maker posted mixed 1Q 2022 financials and at least four Wall Street analysts trimmed their price targets on the stock. Rival makers of insulin pumps, Insulet (PODD) and Medtronic (...

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2022 ...

MedTech firm, Senseonics (NYSE:SENS) joined its partner Ascensia Diabetes Care to announce on Wednesday that the first commercial patient has been implanted with Eversense E3, the company’s next-generation continuous glucose monitoring system. The U.S. launch of Eversense E3 comes week...